InvestorsHub Logo
Followers 134
Posts 3750
Boards Moderated 0
Alias Born 01/28/2006

Re: MinnieM post# 307246

Wednesday, 07/01/2020 12:54:31 AM

Wednesday, July 01, 2020 12:54:31 AM

Post# of 403174
Brilacidin should be moving up the list. The RBL studies show very positive in vitro activity against Covid 19.

The following have all had disappointing Covid 19 studies published:
Favipirvir,Chloroquine,Acterma,Ritonavir,Remdesivir,Kevsara, Sarilumab.

Cynk-001 Has reported antiviral and anti-inflammatory properties according to the company. I could find not reports of any kind of Coronavirus in vitro studies US studies. Chinese in vitro reports seem without much factual evidence.

BDB-1 Is a monoclonal antibody against complement factor C5a a component of the inflammatory complement cascade. It is reported to decrease inflammmation. The Chinese company is reporting a trial in healthy volunteers was successful and it is to enter clinical trials in Europe.

Rintatolimod is an anti inflammatory previously studied as an AIDS drug. It is approved as a treatment for chronic fatigue in Argentina. It is set to be studied in Argentina and Japan in a Covid 19 trial.

BCG is an old TB accine which may have anti-inflammatory effects.

Ino-4800 Inovio has reported signs of immune response in its Phase 1 trial.

So Brilacidin, a therapeutic,and INO-4800, a vaccine, are the most successful therapies in the list to date.

We will have a better idea where they stand in a few months.

JMO I would be happy to have anyone post additional information on the pharmaceuticals above.

GLTA,Farrell
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News